Free Fatty Acid Receptor 1 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)- Pipeline Review, H2 2019’, provides in depth analysis on Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders, Gastrointestinal, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Oncology and Respiratory under development targeting Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

– The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Amgen Inc

Cadila Healthcare Ltd

Caldan Therapeutics Ltd

Daiichi Sankyo Co Ltd

Hyundai Pharmaceutical Co Ltd

Johnson & Johnson

Liminal BioSciences Inc

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Companies Involved in Therapeutics Development

Amgen Inc

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

Hyundai Pharmaceutical Co Ltd

Johnson & Johnson

Merck & Co Inc

Takeda Pharmaceutical Co Ltd

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drug Profiles

AM-1638 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3189 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1558 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasiglifam Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2305 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR40 for Type 2 Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYDG-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Product Development Milestones

Featured News & Press Releases

Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development

Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes

May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society

Aug 22, 2012: Takeda Launches Phase III Clinical Trial In Asia For TAK-875 To Treat Diabetes

Feb 27, 2012: Takeda Announces Publication Of Phase II Data Of TAK-875 In The Lancet, Demonstrates Improved Glycemic Control In Patients With Type 2 Diabetes

Oct 18, 2011: Takeda Initiates Phase III Clinical Trial Program In US, Latin America, And Europe For Investigational Type 2 Diabetes Therapy TAK-875

Sep 12, 2011: Takeda's TAK-875 Enters Into Phase III Clinical Trials For Treatment Of Type 2 Diabetes In Japan

Jun 28, 2011: Takeda Presents Late Breaking Data Of TAK-875 At American Diabetes Association 71st Annual Scientific Sessions

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Amgen Inc, H2 2019

Pipeline by Cadila Healthcare Ltd, H2 2019

Pipeline by Caldan Therapeutics Ltd, H2 2019

Pipeline by Daiichi Sankyo Co Ltd, H2 2019

Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019

Pipeline by Johnson & Johnson, H2 2019

Pipeline by Liminal BioSciences Inc, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by Scohia Pharma Inc, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Pipeline by TiumBio Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports